BioSig (BSGM) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38659
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Entity Central Index Key	0001530766
Entity Tax Identification Number	26-4333375
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	12424 Wilshire Blvd Suite 745
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90025
City Area Code	(203)
Local Phone Number	409-5444
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,278,346
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash	$ 2,104	$ 190
Accounts receivable	54	24
Employee advance		5
Net investment in leases, short term	65	103
Prepaid expenses and vendor deposits	163	206
Total current assets	2,386	528
Property and equipment, net	137	509
Right-to-use assets, net	257	412
Other assets:
Net investment in leases, long term	4	17
Patents, net	279	288
Other assets	44	44
Total assets	3,107	1,798
Current liabilities:
Accounts payable and accrued expenses, including $15 and $30 to related parties as of June 30, 2024 and December 31, 2023, respectively	2,604	4,116
Customer deposits		16
Dividends payable	105	101
Lease liability, short term	267	349
Total current liabilities	2,976	4,582
Long term liabilities:
Lease liability, long term	15	103
Total long term liabilities	15	103
Total liabilities	2,991	4,685
Commitments and contingencies (Note 12)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of June 30, 2024 and December 31, 2023	105	105
Deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of June 30, 2024 and December 31, 2023 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 15,110,846 and 9,040,043 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	15	9
Additional paid in capital	252,311	241,988
Accumulated deficit	(252,332)	(245,015)
Total stockholders’ deficit attributable to BioSig Technologies, Inc.	(6)	(3,018)
Non-controlling interest	17	26
Total equity (deficit)	11	(2,992)
Total liabilities and equity (deficit)	$ 3,107	$ 1,798

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,110,846	9,040,043
Common stock, shares outstanding	15,110,846	9,040,043
Series C 9% Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, stated value	$ 1,000	$ 1,000
Temporary equity, shares authorized	4,200	4,200
Temporary equity, shares issued	105	105
Temporary equity, shares outstanding	105	105
Temporary equity, shares liquidation preference	$ 105	$ 105
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series C Preferred Stock [Member]
Preferred stock, shares authorized	4,200	4,200
Preferred stock, shares outstanding	105	105
Series D Preferred Stock [Member]
Preferred stock, shares authorized	1,400	1,400
Series E Preferred Stock [Member]
Preferred stock, shares authorized	1,000	1,000
Series F Preferred Stock [Member]
Preferred stock, shares authorized	200,000	200,000
Related Party [Member]
Accounts payable and accrued expenses, related parties	$ 15	$ 30

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 13		$ 27	$ 5
Operating expenses:
Research and development	342	1,709	580	2,771
General and administrative	4,914	9,107	7,796	15,352
Impairment of long term assets			253
Depreciation and amortization	49	92	127	176
Total operating expenses	5,305	10,908	8,756	18,299
Loss from operations	(5,292)	(10,908)	(8,729)	(18,294)
Other income (expense):
Interest income, net	(5)	3	(8)	7
Gain on settlement and forgiveness of accounts payable	1,388		1,388
Other income (expense), net:	(2)	(225)	23	(225)
Loss before income taxes	(3,911)	(11,130)	(7,326)	(18,512)
Income taxes (benefit)
Net loss	(3,911)	(11,130)	(7,326)	(18,512)
Non-controlling interest	(4)	37	9	87
Net loss attributable to BioSig Technologies, Inc.	(3,915)	(11,093)	(7,317)	(18,425)
Preferred stock dividend	(3)	(3)	(5)	(5)
Preferred stock deemed dividend			(133)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (3,918)	$ (11,096)	$ (7,455)	$ (18,430)
Net loss per common share, basic	$ (0.30)	$ (1.58)	$ (0.65)	$ (2.80)
Net loss per common share, diluted	$ (0.30)	$ (1.58)	$ (0.65)	$ (2.80)
Weighted average number of common shares outstanding, basic	12,916,272	7,028,156	11,386,266	6,587,850
Weighted average number of common shares outstanding, diluted	12,916,272	7,028,156	11,386,266	6,587,850

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity - USD ($)	Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 5,000		$ 216,282,000	$ (215,974,000)	$ (21,000)	$ 292,000
Balance, shares at Dec. 31, 2022	5,505,068
Common stock issued for services		[1]	1,097,000			1,097,000
Common stock issued for services, shares	116,750
Sale of common stock and warrants, net transactional costs	$ 1,000		6,747,000			6,748,000
Sale of common stock and warrants, net transactional costs, shares	850,030
Stock based compensation		[1]	1,047,000		5,000	1,052,000
Stock based compensation, shares	249,125
Preferred stock dividend			(2,000)			(2,000)
Net loss				(7,332,000)	(50,000)	(7,382,000)
Common stock issued in settlement of accounts payable		[1]	105,000			105,000
Common stock issued in settlement of accounts payable, shares	8,800
Balance at Mar. 31, 2023	$ 6,000		225,276,000	(223,306,000)	(66,000)	1,910,000
Balance, shares at Mar. 31, 2023	6,729,773
Balance at Dec. 31, 2022	$ 5,000		216,282,000	(215,974,000)	(21,000)	292,000
Balance, shares at Dec. 31, 2022	5,505,068
Preferred stock dividend						(5,000)
Net loss						(18,512,000)
Balance at Jun. 30, 2023	$ 7,000		234,635,000	(234,399,000)	89,000	331,000
Balance, shares at Jun. 30, 2023	7,389,740
Balance at Mar. 31, 2023	$ 6,000		225,276,000	(223,306,000)	(66,000)	1,910,000
Balance, shares at Mar. 31, 2023	6,729,773
Common stock issued for services		[1]	4,811,000			4,811,000
Common stock issued for services, shares	385,434
Sale of common stock and warrants, net transactional costs	$ 1,000		3,245,000			3,245,000
Sale of common stock and warrants, net transactional costs, shares	259,090
Stock based compensation		[1]	(73,000)		4,000	(69,000)
Stock based compensation, shares	11,083
Preferred stock dividend			(3,000)			(3,000)
Net loss				(11,093,000)	(37,000)	(11,130,000)
Sale of subsidiary stock			1,379,000		188,000	1,567,000
Common stock issued for exercise of warrants cashless		[1]
Common stock issued for exercise of warrants cashless, shares	4,360
Balance at Jun. 30, 2023	$ 7,000		234,635,000	(234,399,000)	89,000	331,000
Balance, shares at Jun. 30, 2023	7,389,740
Balance at Dec. 31, 2023	$ 9,000		241,988,000	(245,015,000)	26,000	(2,992,000)
Balance, shares at Dec. 31, 2023	9,040,043
Common stock issued for services	$ 2,000		1,249,000			1,251,000
Common stock issued for services, shares	1,862,744
Sale of common stock and warrants, net transactional costs		[2]	1,040,000			1,040,000
Sale of common stock and warrants, net transactional costs, shares	260,720
Stock based compensation		[2]	(190,000)			(190,000)
Stock based compensation, shares	1,500
Accretion of deemed preferred stock dividend			133,000			133,000
Deemed preferred stock dividend			(133,000)			(133,000)
Preferred stock dividend			(2,000)			(2,000)
Net loss				(3,402,000)	(13,000)	(3,415,000)
Balance at Mar. 31, 2024	$ 11,000		244,085,000	(248,417,000)	13,000	(4,308,000)
Balance, shares at Mar. 31, 2024	11,165,007
Balance at Dec. 31, 2023	$ 9,000		241,988,000	(245,015,000)	26,000	(2,992,000)
Balance, shares at Dec. 31, 2023	9,040,043
Preferred stock dividend						(5,000)
Net loss						(7,326,000)
Balance at Jun. 30, 2024	$ 15,000		252,311,000	(252,332,000)	17,000	11,000
Balance, shares at Jun. 30, 2024	15,110,846
Balance at Mar. 31, 2024	$ 11,000		244,085,000	(248,417,000)	13,000	(4,308,000)
Balance, shares at Mar. 31, 2024	11,165,007
Common stock issued for services		[2]	420,000			420,000
Common stock issued for services, shares	278,000
Sale of common stock and warrants, net transactional costs			635,000			636,000
Sale of common stock and warrants, net transactional costs, shares	434,782
Stock based compensation	$ 1,000		4,011,000			4,012,000
Stock based compensation, shares	1,238,750
Preferred stock dividend			(3,000)			(3,000)
Net loss				(3,915,000)	4,000	(3,911,000)
Common stock issued in exchange for principal and accrued interest on a note payable		[2]	509,000			509,000
Common stock issued in exchange for principal and accrued interest on a note payable, shares	348,624
Sale of common stock and warrants, net transactional costs	$ 2,000		2,532,000			2,534,000
Sale of common stock and warrants, net transactional costs, shares	1,570,683
Stock issued as forgiveness of accounts payable		[2]	122,000			122,000
Stock issued as forgiveness of accounts payable, shares	75,000
Balance at Jun. 30, 2024	$ 15,000		$ 252,311,000	$ (252,332,000)	$ 17,000	$ 11,000
Balance, shares at Jun. 30, 2024	15,110,846
[1]- less than $1[2]- less than $1

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Sale of common stock and warrants, net transactional costs	$ 201	$ 482

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,326)	$ (18,512)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	127	176
Non-cash lease expense	155	144
Non-cash inventory write-down		1,307
Impairment of long-term assets	253
Gain on settlement and forgiveness of accounts payable	1,388
Equity based compensation	5,493	6,891
Changes in operating assets and liabilities:
Accounts receivable	(30)	(12)
Lease receivables	51	50
Employee advances	5	(5)
Inventory		(19)
Prepaid expenses and other	42	(564)
Deferred revenue		(5)
Customer deposits	(7)
Accounts payable and accrued expenses	(2,776)	159
Operating lease liabilities	(170)	(153)
Net cash used in operating activities	(2,795)	(10,543)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(122)
Net cash used in investing activity		(122)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of related party note payable	500
Proceeds from sale of common stock and warrants, net of issuance costs	4,209	9,993
Proceeds from the sale of subsidiary stock to non-controlling interest, net of issuance costs		1,567
Net cash provided by financing activities	4,709	11,560
Net increase in cash and cash equivalents	1,914	895
Cash, beginning of the period	190	357
Cash, end of the period	2,104	1,252
Supplemental disclosures of cash flow information:
Cash paid during the period for interest
Cash paid during the period for income taxes
Noncash investing and financing activities:
Common stock issued in settlement of accounts payable	122	105
Dividend payable on preferred stock charged to additional paid in capital	5	5
Series C convertible preferred stock deemed dividend	133
Common stock issued for conversion of note payable and accrued interest	$ 509

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	NOTE 1 NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business and organization BioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage. On November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was renamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear had been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. In 2019 and 2020, ViralClear sold an aggregate of 1,965,240 15.6 894,869 69.08 On July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to BioSig AI Sciences, Inc. (“BioSig AI”) on May 31, 2023. The subsidiary was established to pursue clinical needs of cardiac and neurological disorders through recordings and analyses of action potentials. BioSig AI aims to contribute to the advancements of AI-based diagnoses and therapies. At June 30, 2024 and December 31, 2023, the Company had a majority interest in BioSig AI of 84.5 The Company continues to evaluate opportunities for the two subsidiaries. On January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees, effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company’s Chief Operating Officer, and Gray Fleming, the Company’s Chief Commercial Officer and twenty-six employees effective February 20, 2024. The effect of the workforce reductions has significantly reduced operations in the short term. In connection with workforce reduction, the Company issued an aggregate of 85,244 72,065 On March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $ 1.00 5,000,000 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) The letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities of $ 35 On June 10, 2024, the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company’s common stock from Nasdaq due to the Company’s continued non-compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on Nasdaq. As a result, trading in the Company’s common stock will be suspended on Nasdaq effective with the open of business on Wednesday, June 12, 2024. The Company’s common stock should be eligible to trade on the OTC Markets’ Pink Current Information tier under symbol “BSGM” effective with the open of trading on Wednesday, June 12, 2024. The Company seeked the Panel’s reconsideration of its decision in accordance with the Nasdaq Listing Rules On June 24, 2024, the Company was notified by Nasdaq that the Nasdaq Hearings Panel had declined to reconsider its decision dated June 10, 2024 to delist the Company’s common stock from Nasdaq (the “Delisting Decision”). Trading in the Company’s securities was suspended on Nasdaq effective with the open of business on June 12, 2024, at which point the Company’s common stock was eligible to trade on the OTC Market’s Pink Current Information tier. On July 10, 2024, the Company filed a submission in support of an appeal to the Delisting Decision to the Nasdaq Listing and Hearing Review Council and is currently awaiting a decision. On July 23, 2024, the Company commenced trading of its common stock on the OTCQB, operated by OTC Markets Group, Inc. The unaudited condensed consolidated financial statements include the accounts of BioSig Technologies, Inc., and its majority owned subsidiaries, ViralClear and BioSig AI. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023 filed with the Company’s Form 10-K with the Securities and Exchange Commission on April 16, 2024.

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	NOTE 2 GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of June 30, 2024, the Company had cash of $ 2.1 0.6 2.8 The Company’s primary source of operating funds since inception has been cash proceeds from sale of equity securities and issuance of debt. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company’s plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. The Company’s strategic shift to potentially hiring a team of an additional 4-6 persons to execute a business development strategy of finding partners for the commercialization of PURE EP, develop new products in the field of Pulse Field Ablation and to continue to integrate PURE EP into today’s lab equipment will allow the Company to significantly reduce operating expenses. The Company will require additional financing to fund future operations. Further, although the Company began commercial operations, there is no assurance that the Company will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance that the Company’s continuing research and development will be successfully completed or that any additional products will be commercially viable. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows. Reverse Stock Split On January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrade rentals in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 842, Leases Revenue from Contracts with Customers The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Under ASC 606, the Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Performance obligations are the units of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Once the PURE EP Platform is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrade rentals are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP Platform and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s consolidated balance sheet. In 2022, the Company entered two leases for our PURE EP Platform at a rate of $ 4,333 30 one year In 2023, the Company entered into a one-year lease for software upgrade. The Company accounts for the lease in accordance with ASC 606. The Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. Non-lease components are recognized under ASC 606. The discount rate utilized was the contract explicit rate of 2% A reconciliation of contract liabilities with customers for the six months ended June 30, 2024 and 2023, are presented below: SCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS Six months ended June 30,2024: Balance at December 31, 2023 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2024 (000’s) Service revenue $ - $ 27 $ (27 ) $ - BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Six months ended June 30, 2023: Balance at December 31, 2022 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2023 (000’s) Service revenue $ 5 $ - $ (5 ) $ - The Company had one customer which accounts for 100 The Company had one customer which accounts for 96 100 At June 30, 2024, the Company had three customers representing 34.9 31.9 23.9 62.3 19.6 18.0 The Company utilized one contract manufacturer for the manufacture and supply of the PURE EP Platform for the three and six months ended June 30, 2024 and 2023. Deferred Costs (Contract acquisition costs) The Company capitalizes initial and renewal sales commissions in the period the commission is earned, which generally occurs when a customer contract is obtained, and amortize deferred commission costs on a straight-line basis over the expected period of benefit, which we have deemed to be the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less. Allowance for Doubtful Accounts The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $ 0 0 Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At June 30, 2024 and December 31, 2023, deposits in excess of FDIC limits were $ 1.85 nil Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value. Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments. Leases (lessee) The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases. Leases (lessor) The Company classifies contractual lease arrangements entered as a lessor as a sales-type, direct financing or operating lease as described in ASC 842-Leases. For sales-type leases, the Company derecognizes the leased asset and recognizes the lease investment on the balance sheet. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 5 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. During the three and six months ended June 30, 2024, the Company re-assessed its carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $ 0 253 Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $ 0.3 1.7 0.6 2.8 Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of June 30, 2024 and 2023 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2024 June 30, 2023 Series C convertible preferred stock 532,425 50,923 Options to purchase common stock 118,700 530,965 Warrants to purchase common stock 4,951,068 1,017,282 Restricted stock units to acquire common stock 1,541,250 58,000 Totals 7,143,443 1,657,170 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 4,752 4,752 9,504 9,603 Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two ( 2 Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 13 – Segment Reporting). Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiaries, ViralClear and BioSig AI. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the unaudited condensed consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the unaudited condensed consolidated statements of operations. The Company’s equity interest in ViralClear and BioSig AI is 69.08 84.48 30.92 15.52 Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (ASC 480), and ASC 815, Derivatives and Hedging (ASC 815), depending on the specific terms of the warrant agreement. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment as of June 30, 2024 and December 31, 2023 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2024 (000’s) December 31, 2023 (000’s) Computer equipment $ 531 $ 531 Furniture and fixtures 109 109 Manufacturing equipment - 372 Testing/Demo equipment 312 356 Leasehold improvements 84 84 Total 1,036 1,452 Less accumulated depreciation (899 ) (943 ) Property and equipment, net $ 137 $ 509 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 5 During the three and six months ended June 30, 2024, the Company re-assessed its carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $ 0 253,411 Depreciation expenses were $ 43,837 86,680 117,213 166,148

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITY	6 Months Ended
	Jun. 30, 2024
Right To Use Assets And Lease Liability
RIGHT TO USE ASSETS AND LEASE LIABILITY	NOTE 5 RIGHT TO USE ASSETS AND LEASE LIABILITY As of June 30, 2024 and December 31, 2023, the Company had outstanding two 30,544 29,995 expiring through July 31, 2025 On July 8, 2024, the Company terminated a lease for $ 60,000 Right to use assets is summarized below: SCHEDULE OF RIGHT TO USE ASSETS June 30, 2024 (000’s) December 31, 2023 (000’s) Right to use asset $ 995 $ 995 Less accumulated amortization (738 ) (583 ) Right to use assets, net $ 257 $ 412 During the three months ended June 30, 2024 and 2023, the Company recorded $ 71,928 and $ 93,057 as lease expense to current period operations, respectively. During the six months ended June 30, 2024 and 2023, the Company recorded $ 162,715 and $ 184,577 as lease expense to current period operations, respectively. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY June 30, 2024 (000’s) December 31, 2023 (000’s) Total lease liability $ 282 $ 452 Less: short term portion (267 ) (349 ) Long term portion $ 15 $ 103 Maturity analysis under these lease agreements are as follows (000’s): SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS Year ended December 31, 2024 186 Year ended December 31, 2025 106 Total 292 Less: Present value discount (10 ) Lease liability $ 282 Lease expense for the three months ended June 30, 2024 and 2023 was comprised of the following: SCHEDULE OF LEASE EXPENSE June 30, 2024 (000’s) June 30, 2023 (000’s) Operating lease expense $ 68 $ 84 Short-term lease expense 4 7 Variable lease expense - 2 Total $ 72 $ 93 Lease expense for the six months ended June 30, 2024 and 2023 was comprised of the following: June 30, 2024 (000’s) June 30, 2023 (000’s) Operating lease expense $ 143 $ 168 Short-term lease expense 12 14 Variable lease expense 8 3 Total $ 163 $ 185

LEASE RECEIVABLES

LEASE RECEIVABLES	6 Months Ended
	Jun. 30, 2024
Lease Receivables
LEASE RECEIVABLES	NOTE 6 LEASE RECEIVABLES In 2022, the Company entered into two leases for our PURE EP Platform at a rate of $ 4,333 30 one year The Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. The discount rate utilized was the contract explicit rate of 2 4 A reconciliation of lease receivables with customers for the six months ended June 30, 2024 and 2023 are presented below: SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS Six months ended June 30, 2024: Balance at December 31, 2023 (000’s) Recognized in Revenue (000’s) Invoiced to Customer (000’s) Interest Earned (000’s) Unguaranteed Residual Assets (000’s) Balance at June 30, (000’s) Contract asset $ 120 $ - $ (55 ) $ - $ 4 $ 69 Less current portion (103 ) - 40 - (2 ) (65 ) Noncurrent portion $ 17 $ - $ (15 ) - $ 2 $ 4 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Six months ended June 30, 2023: Balance at December 31, 2022 (000’s) Recognized in Revenue (000’s) Invoiced to Customer (000’s) Interest Earned (000’s) Unguaranteed Residual Assets (000’s) Balance at June 30, (000’s) Contract asset $ 221 $ - $ (53 ) $ - $ 3 $ 171 Less current portion (101 ) - (1 ) - - (102 ) Noncurrent portion $ 120 $ - $ (54 ) - $ 3 $ 69 Future cash flows under this lease agreement are as follows (000’s): SCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT Year ended December 31, 2024 53 Year ended December 31, 2025 13 Present value of unguaranteed residual assets 4 Total 70 Less: Present value discount (1 ) Net investment in leases $ 69

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 7 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at June 30, 2024 and December 31, 2023 consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE June 30, 2024 (000’s) December 31, 2023 (000’s) Accrued accounting and legal $ 1,259 $ 1,277 Accrued reimbursements and travel - 9 Accrued consulting 152 804 Accrued research and development expenses 467 802 Accrued marketing 62 333 Accrued office and other 414 290 Accrued payroll 250 601 Accounts payable and accrued expenses $ 2,604 $ 4,116

NOTE PAYABLE-RELATED PARTY

NOTE PAYABLE-RELATED PARTY	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
NOTE PAYABLE-RELATED PARTY	NOTE 8 – NOTE PAYABLE-RELATED PARTY On March 7, 2024, the Company issued a promissory note for $ 500,000 March 7, 2026 12

STOCKHOLDER EQUITY

STOCKHOLDER EQUITY	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDER EQUITY	NOTE 9 STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 0.001 200 600 4,200 1,400 1,000 200,000 Series C Preferred Stock As of June 30, 2024 and December 31, 2023, the Company had 105 2.50 0.5302 132,931 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Common stock On January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split The Company is authorized to issue 200,000,000 0.001 15,110,846 9,040,043 During the six months ended June 30, 2024, the Company issued an aggregate of 75,000 122,250 During the six months ended June 30, 2024, the Company issued an aggregate of 2,140,744 1,670,375 During the six months ended June 30, 2024, the Company issued an aggregate of 1,240,250 Sale of common stock. On January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant to which the Company sold to the investors an aggregate of 260,720 130,363 3.989 3.364 five and one-half years 1,040,000 On May 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company sold to the Investors an aggregate of 783,406 1.4605 391,703 1.398 five and one-half years 1,144,164 634,999 509,165 On May 29, 2024, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the investors (i) in a registered direct offering, 1,570,683 0.001 1.91 1,570,683 1.78 109,948 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)

OPTIONS, RESTRICTED STOCK UNITS

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	NOTE 10 OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS BioSig Technologies, Inc. 2023 Long-Term Incentive Plan On December 27, 2022, the Board of Directors of BioSig Technologies, Inc. approved the 2023 Long-Term Incentive Plan (the “2023 Plan”). The 2023 Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 876,595 However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years 15,718 Options Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options using the based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The following table presents information related to stock options at June 30, 2024: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ Under 9.99 67,000 9.3 66,330 10.00 19.99 39,700 8.6 37,151 20.00 29.99 - - - 30.00 39.99 - - - 40.00 49.99 7,500 4.9 7,500 50.00 59.99 - - - 60.00 69.99 3,000 5.5 3,000 70.00 79.99 1,500 6.2 1,500 118,700 8.7 115,481 A summary of the stock option activity and related information for the Plan for the six months ended June 30, 2024 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2024 603,229 $ 25.67 6.7 $ - Forfeited/expired (484,529 ) $ 28.86 Outstanding at June 30, 2024 118,700 $ 12.62 8.68 $ - Exercisable at June 30, 2024 115,481 $ 12.64 8.71 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig Technologies, Inc. of $ 0.350 The fair value of all options vesting during the three and six months ended June 30, 2024 of $ 157,417 154,735 386,336 639,523 21,550 0.50 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 1.398 391,703 November 2029 1.780 1,570,683 May 2029 2.3875 109,948 May 2029 3.364 130,363 July 2029 3.573 1,399,386 May 2025-November 2028 4.066 25,000 November 2032 4.455 113,005 June 2028 4.466 48,980 November 2028 4.6626 64,982 April 2029 4.9252 56,307 March 2029 4.929 76,997 March 2029 5.1358 116,045 July 2028 7.181 95,761 July 2028 7.502 9,846 July 2028 7.963 88,324 August 2028 9.000 21,709 June 2027 9.596 84,390 January 2029 10.0992 19,118 August 2028 10.26 51,705 September 2028 10.4678 84,296 September 2028 11.30 40,417 October 2028 13.28 96,198 November 2028 14.00 174,013 September 2025 48.00 25,000 February 2025 to July 2026 61.60 56,892 November 2027 4,951,068 During the six months ended June 30, 2024, the Company issued warrants to purchase an aggregate of 2,202,697 1.84 A summary of the warrant activity for six months ended June 30, 2024 is as follows: SCHEDULE OF WARRANT ACTIVITY Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2024 2,748,371 $ 7.40 3.7 $ 1,717,104 Issued 2,202,697 $ 2.28 5.0 - Outstanding at June 30, 2024 4,951,068 $ 4.92 4.0 $ - Vested and expected to vest at June 30, 2024 4,429,002 $ 7.21 3.6 $ - Exercisable at June 30, 2024 4,429,002 $ 5.28 3.9 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $ 0.3501 The fair value of warrants issued for services during the three and six months ended June 31, 2024 and 2023 of $ 0 0 Restricted Stock Units The following table summarizes the restricted stock activity for the six months ended June 30, 2024: SCHEDULE OF RESTRICTED STOCK ACTIVITY Restricted shares issued as of January 1, 2024 163,250 Granted 2,675,000 Vested and issued (1,240,250 ) Forfeited (56,750 ) Total 1,541,250 Comprised of: Vested restricted shares as of June 30, 2024 - Unvested restricted shares as of June 30, 2024 1,541,250 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) On March 1, 2024, the Company granted 500,000 vesting in substantially equal monthly installments over one year 352,550 On April 1, 2024, the Company granted 200,000 vesting in substantially equal monthly installments over one year 140,000 On May 1, 2024, the Company issued 150,000 298,500 On May 1, 2024, the Company granted 50,000 vesting in substantially equal monthly installments over one year On May 30, 2024, the Company granted an aggregate of 1,500,000 650,000 650,000 200,000 June 1, 2024, the Company issued 12,500 25,125 On June 7, 2024, the Company granted an aggregate of 262,500 489,563 Stock based compensation expense related to restricted stock grants was $ 3,650,569 3,570,521 101,822 206,526 1,087,633 ViralClear Pharmaceuticals, Inc. 2019 Long-Term Incentive Plan On September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear Plan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 However, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. Additionally, the vesting period of the grants under the ViralClear Plan will be determined by the Administrator, in its sole discretion, with an expiration period of not more than ten years 2,650,071 ViralClear Options The following table presents information related to stock options at June 30, 2024: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 25,000 0.0 25,000 The fair value of all options vesting during the three and six months ended June 30, 2024 of $ 0 0 0 0 0 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Warrants (ViralClear) The following table presents information related to warrants (ViralClear) at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347 Restricted stock units (ViralClear) The following table summarizes the restricted stock activity for the six months ended June 30, 2024: SCHEDULE OF RESTRICTED STOCK ACTIVITY Restricted shares outstanding at January 1, 2024: 1,078,679 Forfeited (400,000 ) Total restricted shares outstanding at June 30, 2024: 678,679 Comprised of: Vested restricted shares as of June 30, 2024 678,679 Unvested restricted shares as of June 30, 2024 - Total 678,679 Stock based compensation expense related to restricted stock unit grants of ViralClear was $ 0 0 14,535 29,070 0 BioSig AI Sciences, Inc. Warrants (BioSig AI) The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 1.00 130,500 June-July 2028

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
NON-CONTROLLING INTEREST	NOTE 11 NON-CONTROLLING INTEREST On November 7, 2018, the Company formed a subsidiary, now known as ViralClear, to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. As of June 30, 2024 and December 31, 2023, the Company had a majority interest in ViralClear of 69.08 On July 2, 2020, the Company formed an additional subsidiary, now known as BioSig AI Sciences, Inc., to pursue clinical needs of cardiac and neurological disorders through recordings and analyses of action potential. BioSig AI aims to contribute to the advancements of AI-based diagnoses therapies. In June and July 2023, BioSig AI sold 2,205,000 1,971,277 As of June 30, 2024 and December 31, 2023, the Company had a majority interest in BioSig AI of 84.5 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) A reconciliation of ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the three months ended June 30, 2024 (000’s): SCHEDULE OF NON-CONTROLLING INTEREST ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net Income (loss) $ (0 ) $ 27 $ 27 Average Non-Controlling interest percentage of losses 32 % 16 % 15 % Net income (loss) attributable to non-controlling interest $ (0 ) $ 4 $ 4 Net loss attributable to the non-controlling interest for the three months ended June, 2023 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net loss $ (120 ) $ (17 ) $ (137 ) Average Non-Controlling interest percentage of profit/losses 30.8 % 0 % 27 % Net loss attributable to non-controlling interest $ (37 ) $ - $ (37 ) Net loss attributable to the non-controlling interest for the six months ended June 30, 2024 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net Income (loss) $ (41 ) $ 24 $ (17 ) Average Non-Controlling interest percentage of losses 32 % 16 % 52 % Net income (loss) attributable to non-controlling interest $ (13 ) $ 4 $ (9 ) Net loss attributable to the non-controlling interest for the six months ended June, 2023 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net loss $ (281 ) $ (18 ) $ (299 ) Average Non-Controlling interest percentage of profit/losses 31 % 0 % 29 % Net loss attributable to non-controlling interest $ (87 ) $ - $ (87 ) The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2024 (000’s): SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Balance, January 1, 2024 $ (158 ) $ 184 $ 26 Net income (loss) attributable to non-controlling interest (13 ) 4 (9 ) Balance, June 30, 2024 $ (171 ) $ 188 $ 17 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 COMMITMENTS AND CONTINGENCIES Operating leases See Note 5 for operating lease discussion. Licensing agreements 2017 Know-How License Agreement On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date. The Company is obligated to pay to Mayo Foundation a 1 2 4 Patent and Know-How License Agreement EP Software Agreement On November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and import licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company. In connection with the EP Software Agreement, the Company agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $ 625,000 0 Amended and Restated Patent and Know-How License Agreement Tools Agreement On November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of electrophysiology systems. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $ 75,000 In connection with the Tools Agreement, the Company agreed to pay Mayo an upfront consideration of $ 100,000 550,000 0 ViralClear Patent and Know-How License Agreement On November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias in the autonomic nervous system. In connection with the ViralClear Agreement, ViralClear agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $ 700,000 75,000 0 Trek Therapeutics, PBC In the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10 As part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $ 10 5 6 0 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) BioSig AI Sciences, Inc. Consulting Agreement On June 17, 2023, BioSig AI entered into an agreement with Reified Labs LLC (“Reified”) whereby Reified will work with the BioSig AI to develop datasets for the purpose of creating a foundational artificial intelligence platform. The agreement has a one-year term from the effective date and automatically renews for successive one year terms, unless terminated. On January 1, 2024, the contract was terminated. BioSig AI is obligated to pay Reified a monthly consulting fee of $ 30,000 210,000 90,000 Defined Contribution Plan Effective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the three and six months ended June 30, 2024, the Company charged operations $ (47,599) (25,904) 63,818 129,737 Purchase commitments. As of June 30, 2024, the Company had aggregate purchase commitments of approximately $ 1,876,053 Litigation Threatened litigation. On December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination of employment was in retaliation for bringing to the attention of the Company’s board of directors and executives a series of wrongful and questionable practices by members of the Company’s board of directors, Chief Executive Officer and Chief Financial Officer. The claimant sought compensation of in the amount of $ 775,782 On February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the Company’s board of directors. The claimant contends that he and others have sustained losses totaling $ 1,440,000 On March 22, 2024, plaintiff, Michael Gray Fleming (the “Plaintiff”), filed a lawsuit in Hennepin County, Minnesota District Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends that the Company failed to meet its obligations in issuing the Plaintiff stock certificates under the terms of a restricted stock award agreement. Plaintiff is seeking at least $ 288,000 We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Stock-based compensation The Company takes some tax positions, including the reporting of stock-based compensation, that may not be accepted by the Internal Revenue Service upon an examination, and we may be subject to penalties for underreporting of recipient’s income. The result of any such examination is uncertain, and any such penalties could be material to our financial position and results of operations given our current limited cash and revenues.

SEGMENT REPORTING

SEGMENT REPORTING	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 13 SEGMENT REPORTING In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Revenues (from external customers) BioSig $ 13 $ - $ 27 $ 5 ViralClear - - - - BioSig AI Sciences - - - - Revenues $ 13 $ - $ 27 $ 5 Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Operating Expenses: BioSig $ 5,301 $ 10,771 $ 8,708 $ 18,001 ViralClear 4 119 45 280 BioSig AI Sciences - 18 3 18 Operating Expenses $ 5,305 $ 10,908 $ 8,756 $ 18,299 Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Loss from Operations: BioSig $ (5,288 ) $ (10,771 ) $ (8,681 ) $ (17,996 ) ViralClear (4 ) (119 ) (45 ) (280 ) BioSig AI Sciences - (18 ) (3 ) (18 ) Loss from Operations $ (5,292 ) $ (10,908 ) $ (8,729 ) $ (18,294 ) BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) June 30, (000’s) December 31, (000’s) Total Assets BioSig $ 1,797 $ 485 ViralClear - - BioSig AI Sciences 1,310 1,313 Total Assets $ 3,107 $ 1,798

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 14 RELATED PARTY TRANSACTIONS On June 5, 2024, the Company and Mr. Ferdinand Groenewald entered into a consulting agreement (the “Agreement”) effective June 5, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s interim chief financial officer, principal accounting officer and vice president of finance. The Agreement will continue indefinitely until terminated by either party upon 30 days’ advance notice. The Agreement provides for compensation at a fixed rate of $ 15,000 Accounts payable and accrued expenses include due to related parties comprised primarily director fees and travel reimbursements. Due to related parties as of June 30, 2024 and December 31, 2023 was $ 15,000 30,000 On March 1, 2024, the Company issued 500,000 352,550 On March 1, 2024, the Company issued 500,000 352,550 On June 7, 2024, the Company issued 50,000 93,250 On March 7, 2024, the company issued a promissory note to a significant shareholder for $ 500,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date on which these condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its condensed financial statements or disclosures. On July 1, 2024, the Company announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confirming BioSig’s preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig’s common stock to the shareholders of NKC. In addition, at closing, NKC will provide a minimum of $ 2.5 6 On July 1, 2024, the Company issued 62,500 On July 3, 2024, the Company issued 650,000 On July 26, 2024, the Company issued 280,000 114,800 On July 26, 2024, the Company paid $ 25,000 112,500 shares of its common stock as a full settlement of the General Release and Severance Agreement dated January 29, 2023 by and between Steve Chaussy and BioSig Technologies, Inc. (the “Severance Agreement”). Pursuant to the original Severance Agreement, the Company was to pay a cash bonus of $ 200,000 to Steve Chaussy. On August 1, 2024, the Company issued 62,500 On July 15, 2024 the Company terminated its sublease for the office space at 55 Greens Farms Road Westport, Connecticut which was set to end at December 15, 2024.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February 2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Revenue Recognition	Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrade rentals in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 842, Leases Revenue from Contracts with Customers The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Under ASC 606, the Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Performance obligations are the units of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Once the PURE EP Platform is delivered, installed, and accepted by the customer, our performance obligation is recognized. Support, maintenance, and software upgrade rentals are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP Platform and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s consolidated balance sheet. In 2022, the Company entered two leases for our PURE EP Platform at a rate of $ 4,333 30 one year In 2023, the Company entered into a one-year lease for software upgrade. The Company accounts for the lease in accordance with ASC 606. The Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception. Non-lease components are recognized under ASC 606. The discount rate utilized was the contract explicit rate of 2% A reconciliation of contract liabilities with customers for the six months ended June 30, 2024 and 2023, are presented below: SCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS Six months ended June 30,2024: Balance at December 31, 2023 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2024 (000’s) Service revenue $ - $ 27 $ (27 ) $ - BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Six months ended June 30, 2023: Balance at December 31, 2022 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2023 (000’s) Service revenue $ 5 $ - $ (5 ) $ - The Company had one customer which accounts for 100 The Company had one customer which accounts for 96 100 At June 30, 2024, the Company had three customers representing 34.9 31.9 23.9 62.3 19.6 18.0 The Company utilized one contract manufacturer for the manufacture and supply of the PURE EP Platform for the three and six months ended June 30, 2024 and 2023.
Deferred Costs (Contract acquisition costs)	Deferred Costs (Contract acquisition costs) The Company capitalizes initial and renewal sales commissions in the period the commission is earned, which generally occurs when a customer contract is obtained, and amortize deferred commission costs on a straight-line basis over the expected period of benefit, which we have deemed to be the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $ 0 0
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At June 30, 2024 and December 31, 2023, deposits in excess of FDIC limits were $ 1.85 nil
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.
Prepaid Expenses and Vendor Deposits	Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.
Leases (lessee)	Leases (lessee) The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases.
Leases (lessor)	Leases (lessor) The Company classifies contractual lease arrangements entered as a lessor as a sales-type, direct financing or operating lease as described in ASC 842-Leases. For sales-type leases, the Company derecognizes the leased asset and recognizes the lease investment on the balance sheet.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 5 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. During the three and six months ended June 30, 2024, the Company re-assessed its carrying amounts of certain property and equipment due to reduced manufacturing of its commercial products and determined that these carrying amounts exceeded the estimated undiscounted future cash flows. Accordingly, the Company recorded a $ 0 253
Research and Development Costs	Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $ 0.3 1.7 0.6 2.8
Net Income (loss) Per Common Share	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of June 30, 2024 and 2023 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2024 June 30, 2023 Series C convertible preferred stock 532,425 50,923 Options to purchase common stock 118,700 530,965 Warrants to purchase common stock 4,951,068 1,017,282 Restricted stock units to acquire common stock 1,541,250 58,000 Totals 7,143,443 1,657,170
Stock Based Compensation	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.
Patents, Net	Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 4,752 4,752 9,504 9,603
Warranty	Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two ( 2
Segment Information	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 13 – Segment Reporting).
Non-controlling Interest	Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiaries, ViralClear and BioSig AI. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the unaudited condensed consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the unaudited condensed consolidated statements of operations. The Company’s equity interest in ViralClear and BioSig AI is 69.08 84.48 30.92 15.52
Warrants	Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (ASC 480), and ASC 815, Derivatives and Hedging (ASC 815), depending on the specific terms of the warrant agreement. BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS	A reconciliation of contract liabilities with customers for the six months ended June 30, 2024 and 2023, are presented below: SCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS Six months ended June 30,2024: Balance at December 31, 2023 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2024 (000’s) Service revenue $ - $ 27 $ (27 ) $ - BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Six months ended June 30, 2023: Balance at December 31, 2022 (000’s) Consideration Received (000’s) Recognized in Revenue (000’s) Balance at June 30, 2023 (000’s) Service revenue $ 5 $ - $ (5 ) $ -
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2024 June 30, 2023 Series C convertible preferred stock 532,425 50,923 Options to purchase common stock 118,700 530,965 Warrants to purchase common stock 4,951,068 1,017,282 Restricted stock units to acquire common stock 1,541,250 58,000 Totals 7,143,443 1,657,170

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment as of June 30, 2024 and December 31, 2023 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2024 (000’s) December 31, 2023 (000’s) Computer equipment $ 531 $ 531 Furniture and fixtures 109 109 Manufacturing equipment - 372 Testing/Demo equipment 312 356 Leasehold improvements 84 84 Total 1,036 1,452 Less accumulated depreciation (899 ) (943 ) Property and equipment, net $ 137 $ 509

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	6 Months Ended
	Jun. 30, 2024
Right To Use Assets And Lease Liability
SCHEDULE OF RIGHT TO USE ASSETS	Right to use assets is summarized below: SCHEDULE OF RIGHT TO USE ASSETS June 30, 2024 (000’s) December 31, 2023 (000’s) Right to use asset $ 995 $ 995 Less accumulated amortization (738 ) (583 ) Right to use assets, net $ 257 $ 412
SCHEDULE OF LEASE LIABILITY	Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY June 30, 2024 (000’s) December 31, 2023 (000’s) Total lease liability $ 282 $ 452 Less: short term portion (267 ) (349 ) Long term portion $ 15 $ 103
SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS	Maturity analysis under these lease agreements are as follows (000’s): SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS Year ended December 31, 2024 186 Year ended December 31, 2025 106 Total 292 Less: Present value discount (10 ) Lease liability $ 282
SCHEDULE OF LEASE EXPENSE	Lease expense for the three months ended June 30, 2024 and 2023 was comprised of the following: SCHEDULE OF LEASE EXPENSE June 30, 2024 (000’s) June 30, 2023 (000’s) Operating lease expense $ 68 $ 84 Short-term lease expense 4 7 Variable lease expense - 2 Total $ 72 $ 93 Lease expense for the six months ended June 30, 2024 and 2023 was comprised of the following: June 30, 2024 (000’s) June 30, 2023 (000’s) Operating lease expense $ 143 $ 168 Short-term lease expense 12 14 Variable lease expense 8 3 Total $ 163 $ 185

LEASE RECEIVABLES (Tables)

LEASE RECEIVABLES (Tables)	6 Months Ended
	Jun. 30, 2024
Lease Receivables
SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS	A reconciliation of lease receivables with customers for the six months ended June 30, 2024 and 2023 are presented below: SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS Six months ended June 30, 2024: Balance at December 31, 2023 (000’s) Recognized in Revenue (000’s) Invoiced to Customer (000’s) Interest Earned (000’s) Unguaranteed Residual Assets (000’s) Balance at June 30, (000’s) Contract asset $ 120 $ - $ (55 ) $ - $ 4 $ 69 Less current portion (103 ) - 40 - (2 ) (65 ) Noncurrent portion $ 17 $ - $ (15 ) - $ 2 $ 4 BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Six months ended June 30, 2023: Balance at December 31, 2022 (000’s) Recognized in Revenue (000’s) Invoiced to Customer (000’s) Interest Earned (000’s) Unguaranteed Residual Assets (000’s) Balance at June 30, (000’s) Contract asset $ 221 $ - $ (53 ) $ - $ 3 $ 171 Less current portion (101 ) - (1 ) - - (102 ) Noncurrent portion $ 120 $ - $ (54 ) - $ 3 $ 69
SCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT	Future cash flows under this lease agreement are as follows (000’s): SCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT Year ended December 31, 2024 53 Year ended December 31, 2025 13 Present value of unguaranteed residual assets 4 Total 70 Less: Present value discount (1 ) Net investment in leases $ 69

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE	Accounts payable and accrued expenses at June 30, 2024 and December 31, 2023 consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE June 30, 2024 (000’s) December 31, 2023 (000’s) Accrued accounting and legal $ 1,259 $ 1,277 Accrued reimbursements and travel - 9 Accrued consulting 152 804 Accrued research and development expenses 467 802 Accrued marketing 62 333 Accrued office and other 414 290 Accrued payroll 250 601 Accounts payable and accrued expenses $ 2,604 $ 4,116

OPTIONS, RESTRICTED STOCK UNI_2

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2024
SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS	The following table presents information related to stock options at June 30, 2024: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ Under 9.99 67,000 9.3 66,330 10.00 19.99 39,700 8.6 37,151 20.00 29.99 - - - 30.00 39.99 - - - 40.00 49.99 7,500 4.9 7,500 50.00 59.99 - - - 60.00 69.99 3,000 5.5 3,000 70.00 79.99 1,500 6.2 1,500 118,700 8.7 115,481
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of the stock option activity and related information for the Plan for the six months ended June 30, 2024 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2024 603,229 $ 25.67 6.7 $ - Forfeited/expired (484,529 ) $ 28.86 Outstanding at June 30, 2024 118,700 $ 12.62 8.68 $ - Exercisable at June 30, 2024 115,481 $ 12.64 8.71 $ -
SCHEDULE OF OUTSTANDING WARRANTS	The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 1.398 391,703 November 2029 1.780 1,570,683 May 2029 2.3875 109,948 May 2029 3.364 130,363 July 2029 3.573 1,399,386 May 2025-November 2028 4.066 25,000 November 2032 4.455 113,005 June 2028 4.466 48,980 November 2028 4.6626 64,982 April 2029 4.9252 56,307 March 2029 4.929 76,997 March 2029 5.1358 116,045 July 2028 7.181 95,761 July 2028 7.502 9,846 July 2028 7.963 88,324 August 2028 9.000 21,709 June 2027 9.596 84,390 January 2029 10.0992 19,118 August 2028 10.26 51,705 September 2028 10.4678 84,296 September 2028 11.30 40,417 October 2028 13.28 96,198 November 2028 14.00 174,013 September 2025 48.00 25,000 February 2025 to July 2026 61.60 56,892 November 2027 4,951,068
SCHEDULE OF WARRANT ACTIVITY	A summary of the warrant activity for six months ended June 30, 2024 is as follows: SCHEDULE OF WARRANT ACTIVITY Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2024 2,748,371 $ 7.40 3.7 $ 1,717,104 Issued 2,202,697 $ 2.28 5.0 - Outstanding at June 30, 2024 4,951,068 $ 4.92 4.0 $ - Vested and expected to vest at June 30, 2024 4,429,002 $ 7.21 3.6 $ - Exercisable at June 30, 2024 4,429,002 $ 5.28 3.9 $ -
SCHEDULE OF RESTRICTED STOCK ACTIVITY	The following table summarizes the restricted stock activity for the six months ended June 30, 2024: SCHEDULE OF RESTRICTED STOCK ACTIVITY Restricted shares issued as of January 1, 2024 163,250 Granted 2,675,000 Vested and issued (1,240,250 ) Forfeited (56,750 ) Total 1,541,250 Comprised of: Vested restricted shares as of June 30, 2024 - Unvested restricted shares as of June 30, 2024 1,541,250
BioSig AI Sciences, Inc. [Member]
SCHEDULE OF OUTSTANDING WARRANTS	The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 1.00 130,500 June-July 2028
ViralClear Pharmaceuticals, Inc. [Member]
SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS	The following table presents information related to stock options at June 30, 2024: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 25,000 0.0 25,000
SCHEDULE OF OUTSTANDING WARRANTS	The following table presents information related to warrants (ViralClear) at June 30, 2024: SCHEDULE OF OUTSTANDING WARRANTS Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347
SCHEDULE OF RESTRICTED STOCK ACTIVITY	The following table summarizes the restricted stock activity for the six months ended June 30, 2024: SCHEDULE OF RESTRICTED STOCK ACTIVITY Restricted shares outstanding at January 1, 2024: 1,078,679 Forfeited (400,000 ) Total restricted shares outstanding at June 30, 2024: 678,679 Comprised of: Vested restricted shares as of June 30, 2024 678,679 Unvested restricted shares as of June 30, 2024 - Total 678,679

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
SCHEDULE OF NON-CONTROLLING INTEREST	Net loss attributable to the non-controlling interest for the three months ended June 30, 2024 (000’s): SCHEDULE OF NON-CONTROLLING INTEREST ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net Income (loss) $ (0 ) $ 27 $ 27 Average Non-Controlling interest percentage of losses 32 % 16 % 15 % Net income (loss) attributable to non-controlling interest $ (0 ) $ 4 $ 4 Net loss attributable to the non-controlling interest for the three months ended June, 2023 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net loss $ (120 ) $ (17 ) $ (137 ) Average Non-Controlling interest percentage of profit/losses 30.8 % 0 % 27 % Net loss attributable to non-controlling interest $ (37 ) $ - $ (37 ) Net loss attributable to the non-controlling interest for the six months ended June 30, 2024 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net Income (loss) $ (41 ) $ 24 $ (17 ) Average Non-Controlling interest percentage of losses 32 % 16 % 52 % Net income (loss) attributable to non-controlling interest $ (13 ) $ 4 $ (9 ) Net loss attributable to the non-controlling interest for the six months ended June, 2023 (000’s): ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Net loss $ (281 ) $ (18 ) $ (299 ) Average Non-Controlling interest percentage of profit/losses 31 % 0 % 29 % Net loss attributable to non-controlling interest $ (87 ) $ - $ (87 )
SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST	The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2024 (000’s): SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST ViralClear Pharmaceuticals, Inc. (000’s) BioSig AI Sciences, Inc. (000’s) Total (000’s) Balance, January 1, 2024 $ (158 ) $ 184 $ 26 Net income (loss) attributable to non-controlling interest (13 ) 4 (9 ) Balance, June 30, 2024 $ (171 ) $ 188 $ 17

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT REPORTING	Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Revenues (from external customers) BioSig $ 13 $ - $ 27 $ 5 ViralClear - - - - BioSig AI Sciences - - - - Revenues $ 13 $ - $ 27 $ 5 Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Operating Expenses: BioSig $ 5,301 $ 10,771 $ 8,708 $ 18,001 ViralClear 4 119 45 280 BioSig AI Sciences - 18 3 18 Operating Expenses $ 5,305 $ 10,908 $ 8,756 $ 18,299 Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 (000’s) (000’s) (000’s) (000’s) Loss from Operations: BioSig $ (5,288 ) $ (10,771 ) $ (8,681 ) $ (17,996 ) ViralClear (4 ) (119 ) (45 ) (280 ) BioSig AI Sciences - (18 ) (3 ) (18 ) Loss from Operations $ (5,292 ) $ (10,908 ) $ (8,729 ) $ (18,294 ) BIOSIG TECHNOLOGIES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) June 30, (000’s) December 31, (000’s) Total Assets BioSig $ 1,797 $ 485 ViralClear - - BioSig AI Sciences 1,310 1,313 Total Assets $ 3,107 $ 1,798

NATURE OF OPERATIONS AND BASI_2

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)				6 Months Ended		12 Months Ended
	Mar. 05, 2024	Feb. 20, 2024	Jan. 28, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2020	Dec. 31, 2019	Mar. 12, 2024	Dec. 31, 2023
Proceeds from sale of common stock				$ 4,209,000	$ 9,993,000
Market value of listed securities								$ 35,000,000
Minimum [Member]
Share price	$ 1
Proceeds from sale of common stock	$ 5,000,000
Workforce Reduction [Membmer]
Number of shares issued		85,244	85,244
Fair value of common stock		$ 72,065	$ 72,065
BioSig AI Sciences, Inc. [Member]
Equity method investment, ownership percentage				84.50%					84.50%
Viral Clear[Member]
Number of shares issued						1,965,240	1,965,240
Fair value of common stock						$ 15,600,000	$ 15,600,000
Shares issued for acquisition						894,869	894,869
Ownership percentage				69.08%					69.08%

GOING CONCERN AND MANAGEMENT__2

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 2,104		$ 190
Working capital deficit	600
Net cash in operating activities	$ 2,795	$ 10,543

SCHEDULE OF RECONCILIATION OF C

SCHEDULE OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS (Details) - Service [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Product Information [Line Items]
Contract with customer, liability		$ 5
Consideration received	27
Recognized in revenue	(27)	(5)
Contract with customer, liability

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Totals	7,143,443	1,657,170
Share-Based Payment Arrangement, Option [Member]
Totals	118,700	530,965
Warrant [Member]
Totals	4,951,068	1,017,282
Restricted Stock [Member]
Totals	1,541,250	58,000
Series C Preferred Stock [Member]
Totals	532,425	50,923

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Reverse stock split	1-for-10 reverse stock split
Operating leases, rent expense							$ 4,333
Term of contract							30 months
Renewal term of contract							1 year
Lessor sales type lease discount rate				2%
Allowance for doubtful accounts		$ 0		$ 0		$ 0
Bad debt expenses		0	$ 0	0	$ 0
Cash, uninsured amount		1,850,000		1,850,000
Impairment of long-lived assets				253,000
Research and development		342,000	1,709,000	580,000	2,771,000
Amortization		$ 4,752	4,752	$ 9,504	9,603
Warranty term		2 years		2 years
ViralClear Pharmaceuticals, Inc. [Member]
Product Information [Line Items]
Subsidiary, ownership percentage, noncontrolling owner		30.92%		30.92%		30.92%
BioSig AI Sciences, Inc. [Member]
Product Information [Line Items]
Subsidiary, ownership percentage, noncontrolling owner		15.52%		15.52%		15.52%
ViralClear Pharmaceuticals, Inc. [Member]
Product Information [Line Items]
Non-controlling interest rate		69.08%		69.08%		69.08%
BioSig AI Sciences, Inc. [Member]
Product Information [Line Items]
Non-controlling interest rate		84.48%		84.48%		84.48%
Patents [Member]
Product Information [Line Items]
Finite-lived intangible asset, useful life		20 years		20 years
Research and Development Expense [Member]
Product Information [Line Items]
Research and development		$ 300,000	$ 1,700,000	$ 600,000	$ 2,800,000
Minimum [Member]
Product Information [Line Items]
Property, plant and equipment, useful life		3 years		3 years
Maximum [Member]
Product Information [Line Items]
Property, plant and equipment, useful life		5 years		5 years
One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage		100%	100%	96%	100%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				34.90%		62.30%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				31.90%		19.60%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage				23.90%		18%

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total	$ 1,036	$ 1,452
Less accumulated depreciation	(899)	(943)
Property and equipment, net	137	509
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	531	531
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	109	109
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total		372
Testing And Demo Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	312	356
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 84	$ 84

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Impairment of long lived assets			$ 253,411
Depreciation	$ 43,837	$ 86,680	$ 117,213	$ 166,148
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years		5 years

SCHEDULE OF RIGHT TO USE ASSETS

SCHEDULE OF RIGHT TO USE ASSETS (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Right To Use Assets And Lease Liability
Right to use asset	$ 995	$ 995
Less accumulated amortization	(738)	(583)
Right to use assets, net	$ 257	$ 412

SCHEDULE OF LEASE LIABILITY (De

SCHEDULE OF LEASE LIABILITY (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Right To Use Assets And Lease Liability
Total lease liability	$ 282	$ 452
Less: short term portion	(267)	(349)
Long term portion	$ 15	$ 103

SCHEDULE OF MATURITY ANALYSIS U

SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Right To Use Assets And Lease Liability
Year ended December 31, 2024	$ 186
Year ended December 31, 2025	106
Total	292
Less: Present value discount	(10)
Lease liability	$ 282	$ 452

SCHEDULE OF LEASE EXPENSE (Deta

SCHEDULE OF LEASE EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Right To Use Assets And Lease Liability
Operating lease expense	$ 68	$ 84	$ 143	$ 168
Short-term lease expense	4	7	12	14
Variable lease expense		2	8	3
Total	$ 72	$ 93	$ 163	$ 185

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Integer	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) Integer	Jul. 08, 2024 USD ($)
Subsequent Event [Line Items]
Number of leases | Integer			2		2
Operating Lease, Expense			$ 30,544		$ 29,995
Operating Lease, description			expiring through July 31, 2025		expiring through July 31, 2025
Operating lease expense	$ 71,928	$ 93,057	$ 162,715	$ 184,577
Subsequent Event [Member]
Subsequent Event [Line Items]
Termination of Lease Agreement						$ 60,000

SCHEDULE OF RECONCILIATION OF L

SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Sale Leaseback Transaction [Line Items]
Balance	$ 120	$ 221
Recognized in Revenue
Invoiced to Customer	(55)	(53)
Interest Earned
Unguaranteed Residual Assets	4	3
Balance	69	171
Contract Assets Current [Member]
Sale Leaseback Transaction [Line Items]
Balance	103	101
Recognized in Revenue
Invoiced to Customer	40	(1)
Interest Earned
Unguaranteed Residual Assets	2
Balance	65	102
Contract Assets Noncurrent [Member]
Sale Leaseback Transaction [Line Items]
Balance	17	120
Recognized in Revenue
Invoiced to Customer	(15)	(54)
Interest Earned
Unguaranteed Residual Assets	2	3
Balance	$ 4	$ 69

SCHEDULE OF FUTURE CASH FLOWS U

SCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Lease Receivables
Year ended December 31, 2024	$ 53
Year ended December 31, 2025	13
Present value of unguaranteed residual assets	4		$ 3
Total	70
Less: Present value discount	(1)
Net investment in leases	$ 69	$ 120	$ 171	$ 221

LEASE RECEIVABLES (Details Narr

LEASE RECEIVABLES (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2022	Jun. 30, 2023
Lease Receivables
Operating leases, rent expense		$ 4,333
Operating lease, term of contract		30 months
Operating lease, renewal term		1 year
Discount rate	2%
Unguaranteed residual assets	$ 4,000		$ 3,000

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued accounting and legal	$ 1,259	$ 1,277
Accrued reimbursements and travel		9
Accrued consulting	152	804
Accrued research and development expenses	467	802
Accrued marketing	62	333
Accrued office and other	414	290
Accrued payroll	250	601
Accounts payable and accrued expenses	$ 2,604	$ 4,116

NOTE PAYABLE-RELATED PARTY (Det

NOTE PAYABLE-RELATED PARTY (Details Narrative) - Promissory Note [Member]	Mar. 07, 2024 USD ($)
Short-Term Debt [Line Items]
Notes payable	$ 500,000
Due date	Mar. 07, 2026
Interest rate	12%

STOCKHOLDER EQUITY (Details Nar

STOCKHOLDER EQUITY (Details Narrative) - USD ($)					3 Months Ended				6 Months Ended
	May 29, 2024	May 01, 2024	Jan. 31, 2024	Jan. 12, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized					1,000,000				1,000,000	1,000,000
Preferred stock, par or stated value per share (in dollars per share)					$ 0.001				$ 0.001	$ 0.001
Reverse stock split			1-for-10 reverse stock split
Common stock, shares authorized					200,000,000				200,000,000	200,000,000
Common stock, par value					$ 0.001				$ 0.001	$ 0.001
Common stock, shares issued					15,110,846				15,110,846	9,040,043
Common stock, shares outstanding					15,110,846				15,110,846	9,040,043
Number of shares issued for service, value					$ 420,000	$ 1,251,000	$ 4,811,000	$ 1,097,000
Issuance of warrants	109,948				4,951,068				4,951,068
Investor [Member]
Class of Stock [Line Items]
Common stock, par value	$ 0.001
Number of shares sold	1,570,683	783,406		260,720
Warrants to purchase shares	1,570,683	391,703		130,363
Purchase price of warrants				$ 3.989
Exercise price of warrants	$ 1.78	$ 1.398		$ 3.364
Date of issuance		5 years 6 months		5 years 6 months
Value of shares sold		$ 1,144,164		$ 1,040,000
Price per share	$ 1.91	$ 1.4605
Cash		$ 634,999
Conversion of principal and interest		$ 509,165
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares issued									1,240,250
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					200				200	200
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					600				600	600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					4,200				4,200	4,200
Preferred stock, shares issued					105				105	105
Preferred stock, shares outstanding					105				105	105
Deemed dividend									$ 132,931
Series C Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Conversion price					$ 2.50				$ 2.50
Series C Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Conversion price					$ 0.5302				$ 0.5302
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					1,400				1,400	1,400
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					1,000				1,000	1,000
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					200,000				200,000	200,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued forforgiveness of accounts payable									75,000
Number of shares issued for forforgiveness of accounts payable, value									$ 122,250
Number of shares issued for service									2,140,744
Number of shares issued for service, value									$ 1,670,375

SCHEDULE OF EXERCISE PRICE OF S

SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS (Details) - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number of options	118,700	603,229
Options outstanding, Weighted average remaining life	8 years 8 months 12 days
Options exercisable, Number of options	115,481
ViralClear Pharmaceuticals, Inc. [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number of options	25,000
Options outstanding, Weighted average remaining life	0 years
Options exercisable, Number of options	25,000
Options outstanding, Exercise price	$ 5
Options Under 9.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.99
Options outstanding, Number of options	67,000
Options outstanding, Weighted average remaining life	9 years 3 months 18 days
Options exercisable, Number of options	66,330
Options 10.00 - 19.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10
Options outstanding, Number of options	39,700
Options outstanding, Weighted average remaining life	8 years 7 months 6 days
Options exercisable, Number of options	37,151
Options outstanding, Exercise price	$ 19.99
Options 20.00 - 29.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 20
Options outstanding, Number of options
Options exercisable, Number of options
Options outstanding, Exercise price	$ 29.99
Options 30.00 - 39.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 30
Options outstanding, Number of options
Options exercisable, Number of options
Options outstanding, Exercise price	$ 39.99
Options 40.00 - 49.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 40
Options outstanding, Number of options	7,500
Options outstanding, Weighted average remaining life	4 years 10 months 24 days
Options exercisable, Number of options	7,500
Options outstanding, Exercise price	$ 49.99
Options 50.00 - 59.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 50
Options outstanding, Number of options
Options exercisable, Number of options
Options outstanding, Exercise price	$ 59.99
Options 60.00 - 69.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 60
Options outstanding, Number of options	3,000
Options outstanding, Weighted average remaining life	5 years 6 months
Options exercisable, Number of options	3,000
Options outstanding, Exercise price	$ 69.99
Options 70.00 - 79.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 70
Options outstanding, Number of options	1,500
Options outstanding, Weighted average remaining life	6 years 2 months 12 days
Options exercisable, Number of options	1,500
Options outstanding, Exercise price	$ 79.99

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Outstanding shares	603,229
Weighted Average Exercise Price Outstanding	$ 25.67
Weighted-Average Remaining Contractual Term, Outstanding	8 years 8 months 4 days	6 years 8 months 12 days
Outstanding Aggregate Intrinsic Value
Forfeited/expired	(484,529)
Weighted Average Exercise Price Forfeited/expired	$ 28.86
Outstanding shares	118,700	603,229
Weighted Average Exercise Price Outstanding	$ 12.62	$ 25.67
Outstanding Aggregate Intrinsic Value
Outstanding shares Exercisable	115,481
Weighted Average Exercise Price Exercisable	$ 12.64
Weighted-Average Remaining Contractual Term, Exercisable	8 years 8 months 15 days
Outstanding Exercisable Aggregate Intrinsic Value

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANTS (Details) - $ / shares	6 Months Ended
	Jun. 30, 2024	May 29, 2024
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding	4,951,068	109,948
BioSig AI Sciences, Inc. [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 1
Number Outstanding	130,500,000
Expiration date	June-July 2028
ViralClear Pharmaceuticals, Inc. [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding	480,347
Range One [Member] | ViralClear Pharmaceuticals, Inc. [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 5
Number Outstanding	473,772
Expiration date	November 2027
Range Two [Member] | ViralClear Pharmaceuticals, Inc. [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 10
Number Outstanding	6,575
Expiration date	May 2025
Warrants At 1.398 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 1.398
Number Outstanding	391,703
Expiration date	November 2029
Warrants At 1.780 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 1.780
Number Outstanding	1,570,683
Expiration date	May 2029
Warrants At 2.3875 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 2.3875
Number Outstanding	109,948
Expiration date	May 2029
Warrants at 3.364 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 3.364
Number Outstanding	130,363
Expiration date	July 2029
Warrants at 3.573 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 3.573
Number Outstanding	1,399,386
Expiration date	May 2025-November 2028
Warrants at 4.066 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.066
Number Outstanding	25,000
Expiration date	November 2032
Warrants at 4.455 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.455
Number Outstanding	113,005
Expiration date	June 2028
Warrants At 4.466 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.466
Number Outstanding	48,980
Expiration date	November 2028
Warrants At 4.6626 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.6626
Number Outstanding	64,982
Expiration date	April 2029
Warrants At 4.9252 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.9252
Number Outstanding	56,307
Expiration date	March 2029
Warrants At 4.929 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 4.929
Number Outstanding	76,997
Expiration date	March 2029
Warrants At 5.1358 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 5.1358
Number Outstanding	116,045
Expiration date	July 2028
Warrants At 7.181 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 7.181
Number Outstanding	95,761
Expiration date	July 2028
Warrants At 7.502 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 7.502
Number Outstanding	9,846
Expiration date	July 2028
Warrants At 7.963 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 7.963
Number Outstanding	88,324
Expiration date	August 2028
Warrants At 9.000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 9
Number Outstanding	21,709
Expiration date	June 2027
Warrants At 9.596 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 9.596
Number Outstanding	84,390
Expiration date	January 2029
Warrants At 10.0992 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 10.0992
Number Outstanding	19,118
Expiration date	August 2028
Warrants At 10.26 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 10.26
Number Outstanding	51,705
Expiration date	September 2028
Warrants At 10.4678 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 10.4678
Number Outstanding	84,296
Expiration date	September 2028
Warrants At 11.30 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 11.30
Number Outstanding	40,417
Expiration date	October 2028
Warrants At 13.28 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 13.28
Number Outstanding	96,198
Expiration date	November 2028
Warrants At 14.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 14
Number Outstanding	174,013
Expiration date	September 2025
Warrants At 48.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 48
Number Outstanding	25,000
Expiration date	February 2025 to July 2026
Warrants At 61.60 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 61.60
Number Outstanding	56,892
Expiration date	November 2027

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Outstanding shares Beginning	2,748,371
Weighted-Average Exercise Price Beginning	$ 7.40
Weighted-Average Remaining Contractual Term, Outstanding	4 years	3 years 8 months 12 days
Aggregate Intrinsic Value, beginning	$ 1,717,104
Outstanding shares Issued	2,202,697
Weighted-Average Exercise Price Issued	$ 2.28
Weighted-Average Remaining Contractual Term, Issued	5 years
Aggregate Intrinsic Value, Issued
Outstanding shares ending	4,951,068	2,748,371
Weighted-Average Exercise Price Ending	$ 4.92	$ 7.40
Aggregate Intrinsic Value, ending		$ 1,717,104
Warrants Vested and expected to vest, ending	4,429,002
Warrants Vested and expected to vest, Weighted-Average Exercise Price	$ 7.21
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term	3 years 7 months 6 days
Warrants Vested and expected to vest, Aggregate Intrinsic Value
Warrants Exercisable, ending	4,429,002
Warrants Exercisable, Weighted-Average Exercise Price	$ 5.28
Weighted-Average Remaining Contractual Term	3 years 10 months 24 days
Warrants Exercisable, Aggregate Intrinsic Value

SCHEDULE OF RESTRICTED STOCK AC

SCHEDULE OF RESTRICTED STOCK ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total restricted shares outstanding	163,250
Granted	2,675,000
Vested and issued	1,240,250
Forfeited	(56,750)
Total restricted shares outstanding	1,541,250
Vested restricted shares
Unvested restricted shares	1,541,250
ViralClear Pharmaceuticals, Inc. [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total restricted shares outstanding	1,078,679
Forfeited	(400,000)
Total restricted shares outstanding	678,679
Vested restricted shares	678,679
Unvested restricted shares
Total	678,679

OPTIONS, RESTRICTED STOCK UNI_3

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details Narrative) - USD ($)

3 Months Ended

6 Months Ended

Oct. 04, 2024

Jul. 03, 2024

Jun. 07, 2024

Jun. 05, 2024

Jun. 01, 2024

May 30, 2024

May 01, 2024

Apr. 01, 2024

Mar. 01, 2024

Dec. 27, 2022

Sep. 24, 2019

Jun. 30, 2024

Mar. 31, 2024

Jun. 30, 2023

Mar. 31, 2023

Jun. 30, 2024

Jun. 30, 2023

May 29, 2024

Jan. 12, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

Description of terms of award under share-based payment arrangement

the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.

the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder.

Vesting period

10 years

Exercise price

$ 0.350

Fair value of options vested

$ 157,417

$ 154,735

Fair value of options vested

$ 386,336

$ 639,523

Unrecognized compensation expense

21,550

$ 21,550

Weighted average period

6 months

Services, shares

420,000

$ 1,251,000

4,811,000

$ 1,097,000

Share-based payment arrangement, noncash expense

$ 15,000

ViralClear Pharmaceuticals, Inc. [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Fair value of options vested

0

0

$ 0

0

Unrecognized compensation expense

0

$ 0

Employees [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Services, shares

150,000

Services, shares

$ 298,500

Consultants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Services, shares

12,500

Services, shares

$ 25,125

Employees and Board Members [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Services, shares

262,500

Services, shares

$ 489,563

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

$ 0.3501

Unrecognized compensation expense

0

$ 0

Fair value adjustment of warrants

$ 0

0

Investor [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase shares

391,703

1,570,683

130,363

Warrants outstanding exercise price

$ 1.398

$ 1.78

$ 3.364

Investor [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase shares

2,202,697

2,202,697

Warrants outstanding exercise price

$ 1.84

$ 1.84

Share-Based Payment Arrangement, Option [Member] | 2023 Long-Term Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares granted

876,595

Common Stock, Capital Shares Reserved for Future Issuance

15,718

15,718

Share-Based Payment Arrangement, Option [Member] | 2019 Long-Term Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Restricted stock units to purchase up

4,000,000

Expiration period

10 years

Shares remaining

2,650,071

Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Unrecognized compensation expense

$ 1,087,633

$ 1,087,633

Vested, shares

1,240,250

Share-based payment arrangement, noncash expense

3,650,569

101,822

$ 3,570,521

206,526

Restricted Stock Units (RSUs) [Member] | ViralClear Pharmaceuticals, Inc. [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Unrecognized compensation expense

0

0

Share-based payment arrangement, noncash expense

$ 0

$ 14,535

$ 0

$ 29,070

Restricted Stock Units (RSUs) [Member] | Key Consultant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Services, shares

500,000

Vesting year

vesting in substantially equal monthly installments over one year

Services, shares

$ 352,550

Restricted Stock Units (RSUs) [Member] | Employees [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Services, shares

50,000

200,000

Vesting year

vesting in substantially equal monthly installments over one year

vesting in substantially equal monthly installments over one year

Services, shares

$ 140,000

Restricted Stock [Member] | Consultants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Granted restricted, shares

1,500,000

Vested, shares

650,000

Restricted Stock [Member] | Consultants [Member] | Forecast [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Vested, shares

200,000

Restricted Stock [Member] | Consultants [Member] | Subsequent Event [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Vested, shares

650,000

SCHEDULE OF NON-CONTROLLING INT

SCHEDULE OF NON-CONTROLLING INTEREST (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss	$ 27	$ (137)	$ (17)	$ (299)
Average Non-Controlling interest percentage of profit/losses	15%	27%	52%	29%
Net loss attributable to non-controlling interest	$ 4	$ (37)	$ (9)	$ (87)
ViralClear Pharmaceuticals, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss	$ 0	$ (120)	$ (41)	$ (281)
Average Non-Controlling interest percentage of profit/losses	32%	30.80%	32%	31%
Net loss attributable to non-controlling interest		$ (37)	$ (13)	$ (87)
BioSig AI Sciences, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss	$ 27	$ (17)	$ 24	$ (18)
Average Non-Controlling interest percentage of profit/losses	16%	0%	16%	0%
Net loss attributable to non-controlling interest	$ 4		$ 4

SCHEDULE OF CHANGES IN NON-CONT

SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Balance, January 1, 2024			$ 26
Net income (loss) attributable to non-controlling interest	$ 4	$ (37)	(9)	$ (87)
Balance, June 30, 2024	17		17
ViralClear Pharmaceuticals, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Balance, January 1, 2024			(158)
Net income (loss) attributable to non-controlling interest		(37)	(13)	(87)
Balance, June 30, 2024	(171)		(171)
BioSig AI Sciences, Inc. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Balance, January 1, 2024			184
Net income (loss) attributable to non-controlling interest	4		4
Balance, June 30, 2024	$ 188		$ 188

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Jul. 31, 2023	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Noncontrolling Interest [Line Items]
Net proceeds			$ 4,209,000	$ 9,993,000
BioSig AI Sciences, Inc. [Member]
Noncontrolling Interest [Line Items]
Shares issued	2,205,000	2,205,000
Net proceeds	$ 1,971,277	$ 1,971,277
ViralClear Pharmaceuticals, Inc. [Member]
Noncontrolling Interest [Line Items]
Majority interest			69.08%		69.08%
BioSig AI Sciences, Inc. [Member]
Noncontrolling Interest [Line Items]
Majority interest			84.50%		84.50%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 22, 2024	Feb. 22, 2024	Dec. 04, 2023	Jun. 17, 2023	Mar. 15, 2017	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2021	Dec. 31, 2023	Nov. 20, 2019
Loss Contingencies [Line Items]
Charged operations						$ (47,599)	$ (63,818)	$ (25,904)	$ (129,737)
Charged operations						47,599	$ 63,818	25,904	$ 129,737
Aggregate purchase commitments								1,876,053
Compensation expense			$ 775,782
Loss related to litigation settlement		$ 1,440,000
Loss Contingency, Damages Sought, Value	$ 288,000
2017 Know-How License Agreement [Member]
Loss Contingencies [Line Items]
Accounts payable due						4		4			$ 4
2017 Know-How License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage of net sales					1%
2017 Know-How License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage of net sales					2%
EP Software Agreement [Member]
Loss Contingencies [Line Items]
Accounts payable due						0		0			0
Royalty payments												$ 625,000
Tools Agreement [Member]
Loss Contingencies [Line Items]
Accounts payable due						0		0			0
Royalty payments												550,000
Payments for royalties										$ 75,000
Upfront consideration												100,000
Viral Clear Patent Agreement [Member]
Loss Contingencies [Line Items]
Accounts payable due						0		$ 0			0
Royalty payments												$ 700,000
Payments for royalties										$ 75,000
Trek Therapeutics [Member]
Loss Contingencies [Line Items]
Royalty percentage of net sales								6%
Accounts payable due						0		$ 0			0
Consideration received percentage								10%
Trek Therapeutics [Member] | First Country [Member]
Loss Contingencies [Line Items]
Payments for royalties								$ 10,000,000
Trek Therapeutics [Member] | Second Country [Member]
Loss Contingencies [Line Items]
Payments for royalties								5,000,000
Consulting Agreement [Member]
Loss Contingencies [Line Items]
Accounts payable due						$ 210,000		$ 210,000			$ 90,000
Monthly consulting fee				$ 30,000

SCHEDULE OF SEGMENT REPORTING (

SCHEDULE OF SEGMENT REPORTING (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 13		$ 27	$ 5
Operating Expenses	5,305	10,908	8,756	18,299
Loss from Operations	(5,292)	(10,908)	(8,729)	(18,294)
Total Assets	3,107		3,107		$ 1,798
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenues	13		27	5
Operating Expenses	5,301	10,771	8,708	18,001
Loss from Operations	(5,288)	(10,771)	(8,681)	(17,996)
Total Assets	1,797		1,797		485
ViralClear Pharmaceuticals, Inc. [Member]
Segment Reporting Information [Line Items]
Revenues
Operating Expenses	4	119	45	280
Loss from Operations	(4)	(119)	(45)	(280)
Total Assets
BioSig AI Sciences, Inc. [Member]
Segment Reporting Information [Line Items]
Revenues
Operating Expenses		18	3	18
Loss from Operations		$ (18)	(3)	$ (18)
Total Assets	$ 1,310		$ 1,310		$ 1,313

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)				3 Months Ended
	Jun. 07, 2024	Jun. 05, 2024	Mar. 01, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Mar. 07, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Compensation expense		$ 15,000
Common stock issued for services				$ 420,000	$ 1,251,000	$ 4,811,000	$ 1,097,000
Promissory Note [Member]
Related Party Transaction [Line Items]
Notes payable								$ 500,000
Frederick D Hrkac [Member]
Related Party Transaction [Line Items]
Common shares issued			500,000
Common stock issued for services			$ 352,550
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties				$ 15,000					$ 30,000
Chief Executive Officer [Member] | Anthony Amato [Member]
Related Party Transaction [Line Items]
Common shares issued	50,000		500,000
Common stock issued for services	$ 93,250		$ 352,550

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)						3 Months Ended
	Aug. 01, 2024	Jul. 26, 2024	Jul. 16, 2024	Jul. 03, 2024	Jul. 01, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023
Subsequent Event [Line Items]
Unrestricted cash						$ 2,104,000				$ 190,000
Common stock issued for services						$ 420,000	$ 1,251,000	$ 4,811,000	$ 1,097,000
Subsequent Event [Member] | Board Member, Employees and Consultants [Member]
Subsequent Event [Line Items]
Common stock issued for services, shares			280,000
Common stock issued for services			$ 114,800
Subsequent Event [Member] | Steve Chaussy [Member]
Subsequent Event [Line Items]
[custom:CashBonus-0]			$ 200,000
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Number of shares issued				$ 650,000	$ 62,500
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Steve Chaussy [Member]
Subsequent Event [Line Items]
Cash paid		$ 25,000
Number of shares issued		112,500
Subsequent Event [Member] | Vested Restricted Stock Units [Member]
Subsequent Event [Line Items]
Number of shares issued	62,500
Neuro Kinesis Corporation [Member] | Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Unrestricted cash					2,500,000
Neuro Kinesis Corporation [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Unrestricted cash					$ 6,000,000